Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy. 2023

Rosalyn I Marar, and Muhannad Aboud Abbasi, and Sruti Prathivadhi-Bhayankaram, and Andres Daryanani, and Hector Villarraga, and Nandan Anavekar, and Vijaya Raj Bhatt, and Jonas Paludo
Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE.

The field of malignant hematology is transforming with novel immunotherapeutic approaches. Unfortunately, quality of life, treatment efficacy, and life expectancy are negatively affected by cardiotoxic side effects of treatment. To date, the exact mechanism and incidence of cardiotoxicity associated with these therapies is unclear. These events are believed to be triggered or occur concurrently with cytokine release syndrome. Furthermore, there are no formal guidelines to provide evaluation, treatment, and surveillance. We aim to synthesize available literature with updates on the cardiotoxic effects of novel therapies used in malignant hematologic disorders, with a focus on chimeric antigen receptor T-cell therapy and bispecific T-cell engager therapy, along with a proposed algorithm that may guide pretreatment evaluation, monitoring during treatment, and post-treatment surveillance.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011788 Quality of Life A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. HRQOL,Health-Related Quality Of Life,Life Quality,Health Related Quality Of Life
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000076962 Receptors, Chimeric Antigen Synthetic cellular receptors that reprogram T-LYMPHOCYTES to selectively bind antigens. Chimeric Antigen Receptor,Chimeric T-Cell Receptor,Artificial T-Cell Receptors,Chimeric Antigen Receptors,Chimeric Immunoreceptors,Chimeric T-Cell Receptors,Antigen Receptor, Chimeric,Antigen Receptors, Chimeric,Artificial T Cell Receptors,Chimeric T Cell Receptor,Chimeric T Cell Receptors,Immunoreceptors, Chimeric,Receptor, Chimeric Antigen,Receptor, Chimeric T-Cell,Receptors, Artificial T-Cell,Receptors, Chimeric T-Cell,T-Cell Receptor, Chimeric,T-Cell Receptors, Artificial,T-Cell Receptors, Chimeric
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D019337 Hematologic Neoplasms Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES. Blood Cancer,Hematologic Malignancies,Hematopoietic Neoplasms,Hematologic Malignancy,Hematological Malignancies,Hematological Neoplasms,Hematopoietic Malignancies,Malignancies, Hematologic,Malignancy, Hematologic,Neoplasms, Hematologic,Neoplasms, Hematopoietic,Blood Cancers,Cancer, Blood,Hematologic Neoplasm,Hematological Malignancy,Hematological Neoplasm,Hematopoietic Malignancy,Hematopoietic Neoplasm,Malignancy, Hematological,Malignancy, Hematopoietic,Neoplasm, Hematologic,Neoplasm, Hematological,Neoplasm, Hematopoietic
D064987 Cell- and Tissue-Based Therapy Therapies that involve the TRANSPLANTATION of CELLS or TISSUES developed for the purpose of restoring the function of diseased or dysfunctional cells or tissues. Cell Therapy,Tissue Therapy,Therapy, Cell,Therapy, Tissue,Cell and Tissue Based Therapy
D066126 Cardiotoxicity Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION. Cardiac Toxicity,Cardiac Toxicities,Cardiotoxicities,Toxicity, Cardiac

Related Publications

Rosalyn I Marar, and Muhannad Aboud Abbasi, and Sruti Prathivadhi-Bhayankaram, and Andres Daryanani, and Hector Villarraga, and Nandan Anavekar, and Vijaya Raj Bhatt, and Jonas Paludo
July 2022, Heart failure clinics,
Rosalyn I Marar, and Muhannad Aboud Abbasi, and Sruti Prathivadhi-Bhayankaram, and Andres Daryanani, and Hector Villarraga, and Nandan Anavekar, and Vijaya Raj Bhatt, and Jonas Paludo
November 2014, Cancer research,
Rosalyn I Marar, and Muhannad Aboud Abbasi, and Sruti Prathivadhi-Bhayankaram, and Andres Daryanani, and Hector Villarraga, and Nandan Anavekar, and Vijaya Raj Bhatt, and Jonas Paludo
March 2024, British journal of haematology,
Rosalyn I Marar, and Muhannad Aboud Abbasi, and Sruti Prathivadhi-Bhayankaram, and Andres Daryanani, and Hector Villarraga, and Nandan Anavekar, and Vijaya Raj Bhatt, and Jonas Paludo
February 2016, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis,
Rosalyn I Marar, and Muhannad Aboud Abbasi, and Sruti Prathivadhi-Bhayankaram, and Andres Daryanani, and Hector Villarraga, and Nandan Anavekar, and Vijaya Raj Bhatt, and Jonas Paludo
May 2024, Molecular therapy : the journal of the American Society of Gene Therapy,
Rosalyn I Marar, and Muhannad Aboud Abbasi, and Sruti Prathivadhi-Bhayankaram, and Andres Daryanani, and Hector Villarraga, and Nandan Anavekar, and Vijaya Raj Bhatt, and Jonas Paludo
September 2020, Cancers,
Rosalyn I Marar, and Muhannad Aboud Abbasi, and Sruti Prathivadhi-Bhayankaram, and Andres Daryanani, and Hector Villarraga, and Nandan Anavekar, and Vijaya Raj Bhatt, and Jonas Paludo
February 2024, European journal of haematology,
Rosalyn I Marar, and Muhannad Aboud Abbasi, and Sruti Prathivadhi-Bhayankaram, and Andres Daryanani, and Hector Villarraga, and Nandan Anavekar, and Vijaya Raj Bhatt, and Jonas Paludo
November 2023, Transplant infectious disease : an official journal of the Transplantation Society,
Rosalyn I Marar, and Muhannad Aboud Abbasi, and Sruti Prathivadhi-Bhayankaram, and Andres Daryanani, and Hector Villarraga, and Nandan Anavekar, and Vijaya Raj Bhatt, and Jonas Paludo
September 2023, JCO oncology practice,
Rosalyn I Marar, and Muhannad Aboud Abbasi, and Sruti Prathivadhi-Bhayankaram, and Andres Daryanani, and Hector Villarraga, and Nandan Anavekar, and Vijaya Raj Bhatt, and Jonas Paludo
March 2017, Pharmacotherapy,
Copied contents to your clipboard!